| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000024397 |
| Receipt No. | R000028078 |
| Official scientific title of the study | Efficacy and safety of oral immunotherapy combination with omalizumab for severe cow's milk allergy- follow up study- |
| Date of disclosure of the study information | 2016/12/01 |
| Last modified on | 2016/10/13 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Efficacy and safety of oral immunotherapy combination with omalizumab for severe cow's milk allergy- follow up study- | |
| Title of the study (Brief title) | Oral immunotherapy combination with omalizumab for severe cow's milk allergy- follow up study- | |
| Region |
|
|
| Condition | |||
| Condition | food allergy | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To elucidate the efficacy and safety for long period after the randomized study of oral immunotherapy combination with omalizumab for severe cow's milk allergy |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The percentages of sustained unresponsiveness at the months 18 after the start of the randomized study of oral immunotherapy combination with omalizumab for severe cow's milk allergy |
| Key secondary outcomes | The frequencies of allergic reactions from the start to the months 18 after the randomized study of oral immunotherapy combination with omalizumab for severe cow's milk allergy |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | To examine the efficacy and safety for months 18 at the start of the randomized study of oral immunotherapy combination with omalizumab for severe cow's milk allergy | ||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Children who gain desensitization of cow's milk after the randomized study of oral immunotherapy for severe cow's milk allergy and who continue daily cow's milk ingestion.
2. Children who obtain the informed consent of the study |
|||
| Key exclusion criteria | 1. Children who have acute disease and chronic disease except allergic disease.
2.Children or guardian who deny the study 3. Children who were judged as inappropriate by the study director |
|||
| Target sample size | 15 | |||
| Research contact person | |
| Name of lead principal investigator | Shoichiro Taniuchi |
| Organization | Kansai Medical University |
| Division name | Department of Pediatrics |
| Address | 2-5-1, Shinmachi Hirakata city, Osaka, Japan |
| TEL | 072-804-0101 |
| taniuchi@hirakata.kmu.ac.jp | |
| Public contact | |
| Name of contact person | Shoichiro Taniuchi |
| Organization | Kansai Medical University |
| Division name | Department of Pediatrics |
| Address | 2-5-1, Shinmachi Hirakata city, Osaka, Japan |
| TEL | 072-804-0101 |
| Homepage URL | |
| taniuchi@hirakata.kmu.ac.jp | |
| Sponsor | |
| Institute | Kansai Medical University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kansai Medical University |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 関西医科大学 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028078 |